Total
0
Shares
Source: Little Green Pharma
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) has delivered its first shipment of medicinal cannabis oil to France, ahead of the upcoming national trial
  • Earlier this year, LGP won a government tender to be the primary supplier of medicinal cannabis oils for a national trial in France
  • The two-year trial will test the efficacy, safety and quality of medicinal cannabis in up to 3000 patients
  • Notably, if this trial is successful it may lead to the legalisation of medicinal cannabis in France
  • The cannabis oils are expected to be made available to trial patients later this month
  • On the market this afternoon, LGP is up 2.34 per cent and is trading at 65.5 cents per share

Little Green Pharma (LGP) has delivered its first shipment of medicinal cannabis oil to France.

The products have been shipped for the French national medicinal cannabis trial.

In January, LGP won a government tender to be the primary supplier of medicinal cannabis oils for a national trial in France. The two-year trial will test the efficacy, safety and quality of medicinal cannabis in up to 3000 patients.

Notably, if this trial is successful it may lead to the legalisation of medicinal cannabis in France.

The cannabis oils are expected to be made available to trial patients later this month.

Being the primary supplier of this trial, LGP is following its strategy of growing and holding significant market share in key European growth markets, including Germany, the U.K. and France.

Additionally, earlier this week, the company completed its $5 million share purchase plan to help speed up sales and marketing efforts in both Australia and overseas.

On the market this afternoon, LGP is up 2.34 per cent and is trading at 65.5 cents per share at 12:44 pm AEDT.

LGP by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.